6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid has been researched along with alitretinoin in 2 studies
| Studies (6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid) | Trials (6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid) | Recent Studies (post-2010) (6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid) | Studies (alitretinoin) | Trials (alitretinoin) | Recent Studies (post-2010) (alitretinoin) |
|---|---|---|---|---|---|
| 7 | 0 | 0 | 854 | 47 | 269 |
| Protein | Taxonomy | 6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid (IC50) | alitretinoin (IC50) |
|---|---|---|---|
| retinoic acid receptor alpha isoform 1 | Homo sapiens (human) | 0.0084 | |
| retinoic acid receptor RXR-alpha isoform a | Homo sapiens (human) | 0.0189 | |
| Retinoic acid receptor alpha | Homo sapiens (human) | 0.007 | |
| Retinoic acid receptor beta | Homo sapiens (human) | 0.007 | |
| Retinoic acid receptor alpha | Mus musculus (house mouse) | 0.031 | |
| Retinoic acid receptor gamma | Homo sapiens (human) | 0.017 | |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | 0.0305 | |
| Retinoic acid receptor RXR-alpha | Mus musculus (house mouse) | 0.082 | |
| Retinoic acid receptor RXR-beta | Homo sapiens (human) | 0.012 | |
| Retinoic acid receptor RXR-gamma | Homo sapiens (human) | 0.004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chao, WR; Dawson, MI; Feng, KC; Fontana, JA; Hobbs, PD; Jong, L; Pan, C; Xiao, D; Zhang, XK | 1 |
| Hong, WK; Lotan, D; Lotan, R; Oridate, N; Wan, H | 1 |
2 other study(ies) available for 6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid and alitretinoin
| Article | Year |
|---|---|
4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
Topics: Benzoates; Heterocyclic Compounds; Humans; Naphthalenes; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Tumor Cells, Cultured | 2000 |
Overexpression of retinoic acid receptor beta in head and neck squamous cell carcinoma cells increases their sensitivity to retinoid-induced suppression of squamous differentiation by retinoids.
Topics: 3T3 Cells; Alitretinoin; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Differentiation; Drug Resistance; Head and Neck Neoplasms; Humans; Mice; Naphthalenes; Neoplasm Proteins; Receptors, Retinoic Acid; Retinoids; RNA, Messenger; RNA, Neoplasm; Transcription Factor AP-1; Transfection; Tretinoin; Tumor Cells, Cultured | 1999 |